Search

Your search keyword '"Samia Gonzalez"' showing total 3 results
Start Over Author "Samia Gonzalez" Language english
3 results on '"Samia Gonzalez"'

1. Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia

Author

Samia Gonzalez, A. Arnaud, Jean-Christophe Gris, Claire Lozano, Sophie Brun, Julien Crouzet, Philippe Gaulard, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Cancer Research, biology, business.industry, medicine.medical_treatment, Lymphocyte, CD3, Splenectomy, Complete remission, chemical and pharmacologic phenomena, Hematology, medicine.disease, Leukemia, Text mining, medicine.anatomical_structure, Oncology, Immunology, biology.protein, Medicine, business, T-Cell Large Granular Lymphocyte Leukemia, CD8, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

T-cell large granular lymphocyte (T-LGL) leukemia is a lymphoproliferative disease classically defined by an excess of circulating clonal T-LGL (> 0.4 G/L), evidence of abnormal CD3+, CD8+, CD57+ m...

Published
2019

2. Autocrine proliferative effects of hGH are maintained in primary cultures of human mammary carcinoma cells

Author

Jean Chiesa, Cécile M. Vouyovitch, Samia Gonzalez, Zhengsheng Wu, Pierre Mares, Hichem C. Mertani, Jean-Jacques Diaz, Gérard Morel, Peter E. Lobie, Tao Zhu, Catherine Ferrer, Cécile Arnould, Laboratoire de Cytogénétique, Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ), Equipe 8, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre de génétique et de physiologie moléculaire et cellulaire ( CGPhiMC ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Service de gynécologie obstétrique, Hôpital Universitaire Carémeau [Nîmes], Equipe 4, Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), The Liggins Institute and the National Research Centre for Growth and Development, University of Auckland [Auckland], Department of Molecular Medicine and Pathology, Institut de biologie et chimie des protéines [Lyon] ( IBCP ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre de génétique et de physiologie moléculaire et cellulaire (CGPhiMC), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)

Subjects
MESH: Carcinoma, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Cell, MESH : Aged, Stimulation, MESH : Breast Neoplasms, Biochemistry, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Endocrinology, MESH: Aged, 80 and over, MESH : Tumor Cells, Cultured, Tumor Cells, Cultured, MESH: Human Growth Hormone, MESH : Cell Proliferation, MESH : Female, Receptor, Aged, 80 and over, MESH: Aged, 0303 health sciences, MESH: Middle Aged, Chemistry, Human Growth Hormone, MESH : Carcinoma, Middle Aged, MESH : Adult, 3. Good health, Autocrine Communication, medicine.anatomical_structure, 030220 oncology & carcinogenesis, embryonic structures, Female, MESH: Membrane Proteins, MESH : Autocrine Communication, hormones, hormone substitutes, and hormone antagonists, Adult, medicine.medical_specialty, endocrine system, Context (language use), Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Internal medicine, MESH: Cell Proliferation, medicine, Humans, MESH : Middle Aged, MESH: Tumor Cells, Cultured, MESH : Human Growth Hormone, Autocrine signalling, MESH : Aged, 80 and over, 030304 developmental biology, Aged, Cell Proliferation, MESH: Humans, Biochemistry (medical), Carcinoma, MESH : Humans, Antagonist, Membrane Proteins, MESH: Adult, Epithelium, In vitro, MESH : Membrane Proteins, MESH: Autocrine Communication, MESH: Female, MESH: Breast Neoplasms
Abstract

International audience; CONTEXT: Empirical evidence suggests that autocrine human GH (hGH) may possess a proliferative and oncogenic role in human mammary carcinoma. However, this concept is largely derived from studies using cultured human mammary carcinoma cell (HMCC) lines. OBJECTIVE: We investigated the expression and functionality of hGH and the hGH receptor in isolated cultures of primary HMCC. Design: Epithelial cell adhesion molecule-positive primary HMCC were isolated from surgical biopsies of patients with mammary carcinoma and cultured in vitro. Expression of hGH and hGH receptor was determined by RT-PCR, immunofluorescence microscopy, and ELISA. The proliferative response of the cultured primary HMCC to hGH stimulation or hGH inhibition with a hGH antagonist was determined. RESULTS: One hundred percent of cultured primary HMCC expressed the hGH receptor, and 52% expressed hGH at the mRNA level. hGH-positive primary HMCC produced hGH protein within the cell and secreted hGH to the media. Both hGH-negative and hGH-positive HMCC responded to hGH stimulation with large increases in cell number. hGH-positive HMCC responded to inhibition of hGH by a hGH antagonist with a decrease in cell number, whereas hGH-negative HMCC did not. CONCLUSION: Primary HMCC proliferate in response to hGH, and the proliferation of hGH-positive HMCC is inhibited by hGH antagonism. Inhibition of hGH in patients with mammary carcinoma may therefore limit tumor growth.

Published
2011

3. Prognostic value of combined p53 and survivin in pT1G3 urothelial carcinoma of the bladder.

Author

Samia Gonzalez, Sébastien Aubert, Olivier Kerdraon, Olivier Haddad, Jean-Christophe Fantoni, Jacques Biserte, Xavier Leroy, Gonzalez, Samia, Aubert, Sébastien, Kerdraon, Olivier, Haddad, Olivier, Fantoni, Jean-Christophe, Biserte, Jacques, and Leroy, Xavier

Subjects
*BLADDER cancer, *TUMORS, *SURGICAL excision, *PROGNOSIS, *P53 antioncogene
Abstract

pT1G3 bladder tumors have a high tendency to recur and progress. We evaluated the prognostic values of the depth of submucosal invasion and immunostaining with survivin and p53 in 30 pT1G3 urothelial carcinomas at the first endoscopic resection. The depth of invasion was evaluated toward the muscularis mucosa and measured using a micrometer. Survivin and p53 immunostaining were performed using an automated immunostainer. Of the patients, 19 (63%) had tumor recurrence, 11 (37%) had tumor progression, 10 (33%) had metastatic spread, and 10 (33%) died of the disease. Infiltration of deep lamina propria (pT1b) and a micrometric measure of 1.5 mm or more were associated with an increased risk of tumor local and/or metastatic progression (P = .03 and P = .02, respectively). A combined high expression of survivin (

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results